Personalized antibiotic strategy aims to prevent deadly infections after kidney transplant
NCT ID NCT07407673
First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times
Summary
This study tests whether giving a daily antibiotic (pivmecillinam) to kidney transplant patients at high risk of bloodstream infections can reduce those infections. 150 participants will receive either the antibiotic or a placebo for 5 months after transplant. The goal is to see if a personalized prevention approach works better than treating everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIBIOTIC PROPHYLAXIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aarhus University Hospital, Department of Nephrology
Aarhus, 8200, Denmark
-
Odense University Hospital, Department of Nephrology
Odense, 5000, Denmark
-
Rigshospitalet, Department of Nephrology
Copenhagen, 2100, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI could outsmart bacteria: a smarter way to choose antibiotics?
- Could the choice of anesthesia quiet the Body's surgical stress response?
- A simple blood test could spot kidney transplant rejection early
- Aging in place: could mobile teams keep nursing home residents out of the hospital?
- Can antibody infusions outperform antibiotics in shielding CAR-T patients from infections?
- Could one blood draw be enough to catch dangerous infections?